Introduction {#sec1-1}
============

β-thalassemia (OMIM no. 613985) is a worldwide prevalent autosomal recessive inherited anemia. Various mutations in the β-globin gene leading to decreased production or complete absence of β chain of hemoglobin (Hb). Recent surveys suggest that about 400,000 infants are born with a serious Hb disorder each year. Although due to inappropriate registration and data collection in many countries the actual figure expected to be much higher than this, but with the available affected birth rate estimate, it is convincing that the disease is considerably affecting the global health resources.\[[@ref1]\] The molecular basis of β-thalassemia is considerable number of mutations, reportedly to be more than 200, affecting the quantity of β-globin chains.\[[@ref2]\]

β-thalassemia major patients suffer from severe anemia with abnormally ineffective erythropoiesis, erythroid marrow expansion, osteopenia, and bone deformities. Repeated blood transfusion for maintaining Hb level result in iron overload, and the need for chelation therapy. However, majority of patients will ultimately develop organ damage, in particular, the heart and liver, with reduced life quality and expectancy.\[[@ref3]\]

In order to reduce the massive burden imposed to patients, their families and the entire society, β-thalassemia prevention programs have been launched and are active in almost all countries with high thalassemia prevalence.\[[@ref4][@ref5]\] Prenatal diagnostic (PND) testing using either chorionic villus sampling and/or amniocentesis, followed by termination of affected pregnancies are routinely practiced in many countries.\[[@ref6]\] Despite the desirable achievements, large decrease in global birth rates of affected babies is indicative of high abortion rate, which is not a suitable choice for many couples. For those who have the devastating experience of a previous abortion therapy following a PND with affected fetus or due to ethical or religious believes, an abortion-free choice should morally be available. Under these circumstances preimplantation genetic diagnosis (PGD) is the only possible alternative.\[[@ref7]\] In PGD, although various method of sampling is available, but usually one or two blastomers are biopsies from the cleavage stage embryos for the purpose of genetic diagnosis. As the diagnosis takes place before embryo transfer, pregnancy termination is avoided.\[[@ref8]\]

However, the main concern with PGD is the high possibility of misdiagnosis due to, mainly allele drop-out (ADO) and contamination. ADO is an extreme form of preferential amplification where one of the two alleles is fail to amplify. For example hemizygous loci under these circumstances result in complete absence of a polymerase chain reaction (PCR) product. Thus, the highest accuracy for PGD can only be achieved when the diagnosis is confirmed for both noninheritance of mutated allele(s) and presence of the wild allele(s). Multiplexing PCR for the mutation(s) with linked informative polymorphic short tandem repeat markers have shown to be quite helpful for the detection of both contamination and ADO.\[[@ref9][@ref10]\]

The causes of ADO are not well understood, but the most important issues receiving attention are: The cell lysis method, PCR conditions, the sequence of the template DNA, the size of the PCR products, and the degradation of target DNA molecule.\[[@ref11][@ref12][@ref13][@ref14][@ref15]\]

Development of sensitive detection methods such as fluorescent PCR\[[@ref16]\] followed by automated analysis using computer software and a higher denaturing temperature in PCR\[[@ref11]\] are effective measures for reducing the rate of ADO, thereby improving the diagnostic accuracy.

In this study, we report development of simple and efficient multiplex single cell PCR protocol for one β-thalassemia trait couple using nested fluorescent PCR followed by restriction enzyme digestion for detection of the normal and mutated alleles. The protocol after extensive validations on single lymphocytes of patients and spare embryos were applied in clinical PGD cycles for this couple. Using complicated protocols needing sophisticated instrumentation or technology restrict the general use of PGD in developing countries. Simple protocols with desired level of sensitivity would be helpful to establish PGD setup in more centers and countries than being offered presently.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Here we describe the PGD clinical cycle offered to one of our couples already confirmed to be carrier of β-thalassemia mutation with a previous therapeutic abortion following a PND procedure. Mother\'s mutation was IVSI-25 bp deletion and the father mutation was IVSII-1 (G\>A).

Ovarian stimulation and oocyte retrieval {#sec2-2}
----------------------------------------

Controlled ovarian stimulation was carried out in an agonist protocol, using gonadotrophin-releasing hormone analogues along with human menopausal gonadotropins or recombinant follicle-stimulating hormone.\[[@ref17][@ref18]\] Transvaginal ultrasound-guided oocyte harvest was performed 36 h after hCG administration.

Intracytoplasmic sperm injection and embryo biopsy procedure {#sec2-3}
------------------------------------------------------------

The details of the *in vitro* fertilization (IVF) and intracytoplasmic sperm injection (ICSI) procedure have been described previously.\[[@ref19]\] Regardless of the sperm quality, ICSI was the method of choice rather than classical IVF to prevent DNA contamination with sperm DNA.\[[@ref20]\]

Lymphocyte preparation {#sec2-4}
----------------------

Lymphocytes were separated by centrifugation through ficollpaque from 10 ml of blood with EDTA anticoagulant, as instructed by the manufacturer. The isolated lymphocytes were then washed in droplets of Ca^2+^/Mg^2+^-free medium, supplemented with 15 mg/ml bovine serum albumin under a layer of mineral oil. Individual single cells were collected under an inverted microscope and transferred into a 0.2 ml thin-wall PCR tube, containing 2.5 μl alkaline lysis buffer (200 mM KOH, 50 mM dithiothreitol). A few microliters of the medium from the last droplet were collected in a second PCR tube to serve as blank. Prior to PCR amplification, the tubes were heated at 65°C for 10 min, to lyse the cells. The blastomers were obtained from spare embryos that were not suitable for transfer or cryopreservation. The embryos were sequentially transferred to two droplets of acidic Tyrode\'s under oil, with a finely drawn Pasteur-pipette and left until the zona pellucid disappeared. The embryos were then transferred to a Ca^2+^/Mg^2+^ free medium and blastomers were separated by gentle up and down blowing. These single blastomers were then washed in fresh droplets of medium and transferred to PCR tubes containing 2.5 μl of alkaline lysis buffer.

Polymerase chain reaction conditions {#sec2-5}
------------------------------------

Five linked microsatellite polymorphic markers flanking the Hb gene, namely D11S1338, D11S1760, D11S1997, D11S4181, and D11S988, were selected to use in this study. These markers proved to be highly informative; with high polymorphism information content score and a low recombination rate in Iranian population. Initial optimization of PCR protocol and informativity tests for selected markers were carried out on 100 ng genomic DNA from each individual. Subsequently, the method was applied to at least 50 single lymphocytes for the informative polymorphic markers combined with mutation specific primers and parameters such as contamination, ADO and amplification rate were calculated. The efficacy of the method was tested on at least 10 single spare blastomers in the same way as it was carried out for the lymphocytes. Appropriate precautions were taken at all the stages to avoid contamination and appropriate genomic DNA and single cells from both heterozygous parents were included in every PCR round.

For PGD workout a two rounds triplex PCR protocol was used in which the product of first round was used as template for the second round. Primers for the first round PCR was a pair of β-globin specific oligonucleotide primers amplifying a larger region harboring the mutation of interest in combination with primers specific for the informative markers \[[Table 1](#T1){ref-type="table"}\]. The reaction mix for the first round contained 1x neutralization buffer (90 mM Tris--HCl pH 8.3, 30 mM KCl and 20 mM HCl) 50 mM KCl, 100 mM Tris--HCl pH 8.3, 0.1 mg/ml gelatin, 2 mM MgCl~2~, 0.2 mM dNTPs, 10 pmole of primers and 1.25 U AmpliTaq Gold. The second round PCR was performed separately for mutations and markers using 3 µl of the first round triplex PCR as template for the second round PCR amplification. All labeled primers contained Cy5 label at their 5' termini \[[Table 2](#T2){ref-type="table"}\].

###### 

Mutations of parents and the linked STR markers included in the study

![](ABR-6-23-g001)

###### 

Primers, restriction enzymes, digestion specificity and fragment sizes following restriction digests

![](ABR-6-23-g002)

After second round PCR amplification, in order to identify paternal mutation, 10 μl of PCR product was digested by *BtscI (BseGI)* restriction enzyme for 2 h at 37°C. The reverse second round primer was modified in such a way to create restriction site on mutant allele for *BtscI* enzyme. Subsequently, digestion profiles were checked by agarose gel electrophoresis.

Analysis of polymerase chain reaction products {#sec2-6}
----------------------------------------------

Three microliters of the fluorescent labeled amplified DNA was mixed with an equal volume of loading dye (0.5% dextran blue in 100% formamide) and denatured by heating at 90°C for 5 min and immediately transferred on ice before its loading on 6% denaturing sequencing grade polyacrylamide gel (Amersham Biosciences, UK). Electrophoresis was done on an Automated Laser Fluorescence Express DNA sequencer (ALF express) from Pharmacia Biotech, Sweden. Fragment analysis was carried out using AlleleLinks software (Pharmacia Biotech) provided by the ALF express DNA sequencer manufacturer.

Embryo transfer procedure {#sec2-7}
-------------------------

Embryo transfer into the uterus was carried out on day 3--5 postinsemination as in regular IVF cycles.

Results {#sec1-3}
=======

Incorporation of fluorescent labeled primers into the PCR products makes the subsequent automated analysis of the fragments possible, through an excitation/detection system. The DNA fragments are recorded as peaks of variable amplitudes corresponding to their concentrations. Using polymorphic linked markers amplification along with the patient\'s mutation, provide the opportunity to ascertain about ADO, contamination and probable recombination. Each triplex PCR was applied on at least 50 single lymphocytes and the rates of amplification, contamination and ADOs were determined. Efficiency and reproducibility of the results were carried out on spare blastomers as well.

The average amplification rate for beta globin gene fragment was 96% on single lymphocytes when D11S988 and D11S1338 markers were amplified along with the mutation. Polymorphic marker amplification rate was 98% and 90% on single lymphocytes for D11S988 and D11S1338 markers, respectively. The amplification rate was slightly lower on spare blastomers compared to that of single lymphocytes. The results of the clinical PGD cycles are summarized in [Table 3](#T3){ref-type="table"}.

###### 

Summary of PGD clinical cycle offered for this family

![](ABR-6-23-g003)

In PGD clinical cycle PCR product for IVSII-1 mutation was subsequently digested with BtscI restriction enzyme. As it is evident in [Figure 1](#F1){ref-type="fig"}, a 496 bp undigested product is corresponding to the normal allele and restriction fragments of 360 and 136 bp correspond to mutant allele. For maternal mutation, the size differences were sufficiently large that would readily detectable using agarose gel electrophoresis system \[[Figure 1](#F1){ref-type="fig"}\]. However, paternal and maternal alleles for D11S988 and D11S1338 were segregated as it was expected \[[Figure 2](#F2){ref-type="fig"}\].

![Agarose gel electrophoresis analysis of polymerase chain reaction (PCR) products of embryonic blastomer amplification. The mother\'s mutation is IVSI-25 deletion and the father\'s one is IVSII-1 G\>A mutation. A 496 bp PCR product was restricted using BtscI enzyme for discrimination of IVSII-1 mutation. The mutant allele digested in to 360 bp and 136 bp fragments and the normal allele remain uncut. Lane 1, 2, 3 are heterozygous mother, 4, 5, 6 heterozygous father, 7, 8, 9 normal embryo and 10, 11, 12 affected embryo. M is 50 bp ladder](ABR-6-23-g004){#F1}

![Fragment analysis of selected markers using Automated Laser Fluorescence express instrument. Lanes 1, 5 and 9 represent amplified polymerase chain reaction fragments of D11S988 microsatellite marker from maternal genomic DNA, paternal genomic DNA and normal embryonic blastomer respectively. Lanes 4, 6 and 17 represent the amplified fragments of D11S1338 marker from maternal genomic DNA, paternal genomic DNA and normal embryonic blastomer, respectively. Lane 10 is size marker](ABR-6-23-g005){#F2}

Discussion {#sec1-4}
==========

At present the application of PGD is covering a broad range of genetic and nongenetic conditions. Carriers of sex-linked, single gene and mitochondrial disorders, those with chromosomal aberrations, women age 35 and over or experiencing recurring pregnancy loss or those with more than one failed fertility treatment could be eligible cases for PGD. Inherited cardiac diseases,\[[@ref21]\] cancers,\[[@ref22][@ref23]\] late-onset disease,\[[@ref24]\] rare diseases\[[@ref25][@ref26]\] are some of the examples for this broad coverage.

β-thalassemia as a most prevalent monogenic disorder in Iran, and many other countries throughout the world could benefit a lot from PGD, as an abortion free diagnostic procedure. Patients who are not willing to take the risk of abortion following PND with an affected fetus outcome benefit a lot from this strong alternative. The family presented here had experience of a previous abortion therapy and expressed their feeling as the most unpleasant experience of their life. The highly painful memories of the previous miscarriage made them to totally drop the idea of another pregnancy.

In PGD, since our starting material for diagnostic purpose is only a single cell, the strategy is predispose to several inherent pitfalls which considerably increase the risk of misdiagnosis comparing to the conventional PND. For any single cell PCR appropriate measures should taken to eliminate these pitfalls; the most devastating ones are contamination and ADO. Multiplex PCR with linked informative polymorphic markers have shown to be quite helpful to overcome and detect these inherent treats of single cell amplification.\[[@ref27]\]

So far various techniques adopted for PGD with different levels of complexity. These strategies are including real-time PCR with FRET hybridization,\[[@ref28]\] direct single cell sequencing,\[[@ref29]\] whole genome amplification,\[[@ref30][@ref31]\] minisequencing,\[[@ref32]\] array-comparative genomic hybridization\[[@ref33]\] and single nucleotide polymophism microarrays.\[[@ref34]\] However highly sophisticated procedures are not suitable for practicing in less developed centers.

De Rycke *et al*. compared the results obtained by nonfluorescent and fluorescent PCR for sickle cell anemia and β-thalassemia. The amplification efficiency dropped from 94% to 78% in conventional PCR, while ADO increased from 8% to 33%.\[[@ref35]\] Findlay *et al*. obtained a low ADO rate of about 4% due to increased sensitivity using fluorescent PCR.\[[@ref15]\]

In addition PGD can be combined with human leukocyte antigen (HLA) typing together with mutation detection to find an HLA compatible newborn for saving an affected sibling\'s life.\[[@ref36]\] Preimplantation testing for HLA typing is an alternative approach of PGD with combined purpose to create a pregnancy with unaffected child and at the same time HLA-matched with the existing affected sibling. Achieving the most success in stem cell transplantation depend on finding an HLA identical healthy sibling to reduce the incidence of bone marrow transplantation complication, but because of limited number of children in families it is estimated that only 25% of patients are able to find an HLA matched donor among family members. Reports from 2 centers in Belgium and Italy for HLA typing combined with PGD covers the following diseases; sickle cell disease, β-thalassemia, Fanconi anaemia, Wiskott--Aldrich' syndrome, chronic granulomatous disease, Duncan syndrome, hyper IgM syndrome, mannosidosis alpha 1, Hurler syndrome, Gaucher disease, Bruton agammaglobulinaemia, Glanzmann thrombasthenia, adrenoleukodystrophy, and for HLA-only typing; acute lymphoblastic leukaemia, severe aplastic anaemia, Diamond--Blackfan anaemia and histiocytosis\[[@ref37]\]

Financial support and sponsorship {#sec2-8}
---------------------------------

Nil.

Conflicts of interest {#sec2-9}
---------------------

There are no conflicts of interest.

The financial support of Vice Chancellor for Research, Isfahan University of Medical Sciences is greatly acknowledged.
